Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04505267 · ClinicalTrials.gov registry record · Phase 1

NBTXR3 and Radiation Therapy for the Treatment of Inoperable Recurrent Non-small Cell Lung Cancer

A Phase 1 study of Stage III Lung Cancer AJCC v8 and Recurrent Lung Non-Small Cell Carcinoma, sponsored by M.D. Anderson Cancer Center.

Active
Registry status
Phase 1
Development phase
34
Enrollment target
1
Study location

NCT04505267 is a Phase 1 study of Stage III Lung Cancer AJCC v8 and Recurrent Lung Non-Small Cell Carcinoma that is active but no longer recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 34 participants, below the 99-participant average among 40 other Stage III Lung Cancer AJCC v8 trials with a reported enrollment target (66% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04505267, a Phase 1 study of Stage III Lung Cancer AJCC v8 and Recurrent Lung Non-Small Cell Carcinoma, is active but no longer recruiting, sponsored by M.D. Anderson Cancer Center.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
34 participants
Enrollment target
1
Study location

Study Summary

This phase I trial investigates the best dose and side effects of NBTXR3 when given together with radiation therapy for the treatment of non-small cell lung cancer that cannot be treated by surgery (inoperable) and has come back (recurrent). NBTXR3 is a radio-enhancer designed to increase the radiotherapy energy dose deposition inside tumor cells. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving NBTXR3 and radiation therapy may increase radiation-dependent tumor cell killing without increasing the radiation exposure of healthy surrounding tissues.

Interventions

  • RADIATION Radiation Therapy
  • OTHER Hafnium Oxide-containing Nanoparticles NBTXR3

Study Locations (1)

Texas

  • M D Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 34 participants
Start Date 2021-02-10
Est. Completion 2026-03-31
Phase Phase 1

Sponsor

M.D. Anderson Cancer Center

2,692 total trials

What the Registry Record Tells You About NCT04505267

The ClinicalTrials.gov registry entry for NCT04505267 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 99-participant average among 40 other Stage III Lung Cancer AJCC v8 trials with a reported enrollment target (66% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.

The record links to 10 conditions, with Stage III Lung Cancer AJCC v8 appearing as the primary indexed condition, and to 2 interventions - of which Radiation Therapy is the first listed.

NCT04505267 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT04505267 about?

NCT04505267 is a clinical study titled "NBTXR3 and Radiation Therapy for the Treatment of Inoperable Recurrent Non-small Cell Lung Cancer". This phase I trial investigates the best dose and side effects of NBTXR3 when given together with radiation therapy for the treatment of non-small cell lung cancer that cannot be treated by surgery (inoperable) and has come back (recurrent). NBTXR3 is a radio-enhancer designed to increase the radiot...

What is the current status of trial NCT04505267?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 34 participants. The study started on 2021-02-10. Estimated completion is 2026-03-31.

What conditions does trial NCT04505267 study?

This clinical trial studies the following conditions: Stage III Lung Cancer AJCC v8, Recurrent Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage I Lung Cancer AJCC v8, Stage IIA Lung Cancer AJCC v8.

What interventions are being tested in trial NCT04505267?

The interventions under investigation include: Radiation Therapy (RADIATION), Hafnium Oxide-containing Nanoparticles NBTXR3 (OTHER).

Who is sponsoring clinical trial NCT04505267?

This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04505267 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Stage III Lung Cancer AJCC v8

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.